• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Senzime and Philips Medical Systems enter development and commercialization partnership

SEZIRegulatory press release15.07.2026 klo 22.00
Download the release

Uppsala, Sweden, July 15, 2026 – Senzime AB announced today that it has entered into a long-term agreement with Philips Electronics Nederland, B.V. through Philips Hospital Patient Monitoring business, a global leader in patient monitoring systems. The collaboration will explore and develop potential future solutions leveraging the companies’ respective proprietary technologies. These solutions are expected to address market segments that complement Senzime’s existing product portfolio and sales channels. The resulting solutions will be commercialized through Philips' global organization. Within Senzime, these solutions will be managed alongside the company’s existing product portfolio and sales channels.

"This is a landmark agreement for Senzime. It will significantly expand our reach into new market segments and multiply our addressable opportunity by tens of thousands of hospitals worldwide. The commercial agreement will operate alongside our existing product portfolio and sales channels, and we expect it to accelerate the global adoption of our core technologies. Upon successful execution, I expect this relationship to become a major contributor to Senzime’s revenues and earnings over the medium to long term. By leveraging our innovations through strategic industry partnerships such as this, we can access market segments that would otherwise be difficult to reach," said Philip Siberg, CEO of Senzime.

To date, Senzime’s monitoring solutions have been used on more than one million patients and are marketed through the company’s direct sales organization in the United States and Germany, as well as through distribution and license partners in more than 30 additional countries. The new agreement with Philips Medical Systems complements Senzime’s existing commercial strategy and is expected to generate new revenue streams through Philips’ extensive sales channels.

For further information, please contact:


Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-07-15 21:00 CEST.

Attachments


Senzime and Philips Medical Systems enter development and commercialization partnership